Status and phase
Conditions
Treatments
About
This study will evaluate the effect and safety of 608 in patients with nr-axSpA.
Full description
The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of 608 compared to placebo in patients with nr-axSpA.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
180 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Qinghong Zhou, BS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal